OWA
DFTX

Opal Wealth Advisors’s Definium Therapeutics DFTX Stock Holding History

Opal Wealth Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,101
Closed -$20.8K – 437
2026
Q1 		$20.8K Buy
+1,101
New +$18.7K ﹤0.01% 597
2024
Q3 		– Sell
-1,101
Closed -$7.94K – 802
2024
Q2 		$7.94K Buy
+1,101
New +$9.63K ﹤0.01% 707

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Opal Wealth Advisors's DFTX Position: Q2 2026 in Review

Opal Wealth Advisors sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 1,101 shares — an estimated $20.8K sold.

Opal Wealth Advisors first reported a position in DFTX in Q2 2024 and held it in 2 quarters. The position peaked at $20.8K in Q1 2026. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Opal Wealth Advisors reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Opal Wealth Advisors sold 1,101 Definium Therapeutics shares in Q2 2026, an estimated $20.8K.
  • Opal Wealth Advisors first reported a position in Definium Therapeutics in Q2 2024 and held it in 2 quarters.
  • Opal Wealth Advisors's Definium Therapeutics position peaked at $20.8K in Q1 2026.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Opal Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.